Medacta Brand Guidelines: The Ticino Joint-Implant Maker Alberto Siccardi Founded in 1999

Castel San Pietro, 1999.

Medacta was founded in 1999 by Alberto Siccardi in Castel San Pietro, a town in the canton of Ticino in southern Switzerland. The company tells its origin as the story of a patient: it says Siccardi set it up after his own experience of orthopaedic procedures convinced him of the need for a new approach to joint replacement, and it describes itself as “founded by a patient.” The company names him as its chairman and former chief executive.

Medacta calls itself a family company, and says that three generations of the Siccardi family have been involved in it. The family link is documented outside the company too: when Medacta came to the stock market in 2019, Reuters reported that the founding Siccardi family would keep control of the business, and the exchange operator SIX noted that the shares sold in the base offering were existing shares offered by members of the family. Francesco Siccardi took over as chief executive in 2019, the company says, the generational change it pairs with its listing.

The company has stayed in Ticino. SIX described Medacta in April 2019 as headquartered in Castel San Pietro and Rancate. The company says that in 2024 it made major investments in its hubs there, and that in 2025 it opened two new buildings in Rancate and Castel San Pietro to expand its production capacity. It says it now operates in more than 70 countries.

An anterior hip approach and a knee family.

Medacta presents itself as much through surgical techniques and surgeon education as through implants. Its own timeline puts two of its defining steps in 2004. That year it introduced AMIS, short for Anterior Minimally Invasive Surgery, which it calls its first minimally invasive hip technique, and it set up the M.O.R.E. Institute, for Medacta Orthopaedic Research and Education, to train and work with surgeons. The AMIS name still runs through its hip catalogue, for example in the AMIStem femoral stems.

In knees, the core family is GMK, which on Medacta’s website covers primary, revision, hinge and partial designs. The company says the GMK Sphere total knee was based on knee anatomy and kinematic studies by the professors Michael Freeman and Vera Pinskerova. Alongside it sits the MOTO partial knee platform, which Medacta offers in medial, lateral and patellofemoral versions. The website also lists shoulder replacement, a spine range and personalised planning tools grouped under the MySolutions name.

When Medacta listed in 2019, Reuters described it as a company that develops and manufactures orthopaedic implants for knees and spines, and SIX described it as an international orthopaedics company specialising in the design and production of orthopaedic products and the development of the surgical techniques that go with them. That pairing of implant and technique is how the company still frames its work.

How orthopaedic makers present themselves.

Orthopaedic device makers sell to a narrow, expert audience: surgeons, theatre teams, hospital buyers and the distributors who serve them. Their brand material is shaped by that audience. Product imagery tends to be precise and technical, with implants rendered as clean metallic objects, often lit against dark or neutral backgrounds so that the form of a stem, a plate or a screw reads clearly.

Clinical imagery sits alongside the renders. X-rays, bone models, anatomical cut-aways and diagrams of a joint or a spinal segment show where a device goes and how it is meant to fit. Many makers also photograph surgeons in theatre, in gowns and masks under surgical lights, and show the trays of instruments that accompany an implant system, laid out in rows that suggest order and completeness.

Education is a large part of the picture. Device makers run training courses, cadaver labs and online technique guides, and much of their visual output is instructional: step-by-step surgical technique documents, animations and videos. Congresses matter too. Large meetings such as the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) and the congress of the European Federation of National Associations of Orthopaedics and Traumatology (EFORT) are where new systems are often shown, on stands designed to carry a brand at scale.

Corporate identities in the field are usually restrained: sans-serif wordmarks, a small set of brand colours and a great deal of white space, with the visual drama left to the product and the clinical image. Many brands also sit inside larger groups, so a single name may appear alongside a parent company’s mark. That makes the typeface, the palette and the treatment of imagery the main tools a maker has for being recognised.

A listing, then sports medicine.

The company’s holding company, Medacta Group SA, joined the SIX Swiss Exchange on 4 April 2019, trading under the ticker MOVE. SIX reported that Medacta opened the Swiss listing season that year, and Reuters noted that it was Switzerland’s first initial public offering of 2019. The exchange’s chief executive used the occasion to praise family-run businesses, and Reuters reported that the founding family would retain control after the sale. Medacta employed roughly 970 people at the time, according to SIX.

Medacta marked its 25th anniversary in 2024 with what it called a World Tour, a series of scientific events in Europe, the United States, Australia and Japan. In 2025 it moved further into sports medicine. ORTHOWORLD reported on 7 March 2025 that Medacta had completed the acquisition of Parcus Medical, a sports-medicine and arthroscopy business, from Anika, on undisclosed terms. Parcus was to be folded into Medacta’s Sportsmed business line, and Medacta was taking over Parcus’s manufacturing site in Florida. Parcus’s products cover procedures in the shoulder, knee, hip, foot and ankle, the report said. Anika had bought Parcus in 2020 and announced in the last quarter of 2024 that it planned to sell it, according to the same report.

Medacta’s chief executive sets out the company’s aims in its own words. On its corporate website Francesco Siccardi says the mission is “to transform the patient experience by developing advanced surgical approaches, implants, and instruments through responsible innovation,” with more collaboration with surgeons and universities and continued investment in medical education and personalised solutions.

Medacta’s public face reflects that mix of a family story and a listed company. Its corporate pages lead with the founder-as-patient account and the phrase “sustainable innovation, world-class surgeon education,” while its investor pages carry the reports and governance documents expected of a Swiss-listed group.

For a design guide, Medacta shows how a founder’s personal story can anchor a technical brand that sells to surgeons. Compare Waldemar Link, another family-controlled European joint-implant maker, and LimaCorporate, an implant maker from neighbouring Italy. For this guide we use a lake blue, an olive sage and a warm stone with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Medacta’s identity on hand — save it to a board in the Made Good inspiration library.